STOCK TITAN

KALA (KALA) files Form 144 for $14.6K insider stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

KALA BIO, Inc. has filed a Form 144 indicating a proposed sale of 3,631 shares of its common stock. The shares are to be sold through E*TRADE Financial on or after 24 June 2025 on the NASDAQ exchange. At the reference market price, the transaction is valued at approximately $14,560. The company reports 6,452,398 shares outstanding, so the contemplated sale represents roughly 0.06% of the float.

The shares were acquired via the vesting of Restricted Stock Units (RSUs) issued as equity compensation on the same date. During the past three months, the same account sold 2,850 shares on 3 June 2025 for gross proceeds of $10,659.

Rule 144 filings are routine administrative notices required before certain affiliate or insider sales. Given the small size relative to total shares and the absence of any disclosed adverse information, the filing appears immaterial to the company’s fundamentals and is unlikely to influence trading dynamics.

Positive

  • None.

Negative

  • None.

Insights

TL;DR — Minor insider sale (0.06% float); no material impact expected.

The Form 144 covers just 3,631 shares, worth about $14.6 K, against a 6.45 M share base. It follows a prior 2,850-share sale earlier in the month. The shares originate from RSU vesting, a routine compensation event. No pricing, strategic, or operational disclosures accompany the notice, and the filer affirms no undisclosed material information. In my view, the transaction is administratively necessary but non-impactful for investors, warranting a neutral stance.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many KALA BIO (KALA) shares are being sold under this Form 144?

3,631 common shares are slated for sale.

What is the approximate market value of the proposed KALA share sale?

The filing lists an aggregate market value of $14,560.31.

When is the planned sale date for the KALA BIO shares?

The approximate sale date disclosed is 24 June 2025.

What percentage of outstanding shares do the 3,631 shares represent?

They equate to roughly 0.06% of the 6,452,398 shares outstanding.

Were there any recent prior sales by the same filer?

Yes. 2,850 shares were sold on 3 June 2025 for $10,659.

How were the shares acquired by the insider?

They were obtained through Restricted Stock Unit vesting as equity compensation.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

18.80M
8.10M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON